A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation-Reference-Cited by-同舟云学术

A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation

Published:2022-05-17 Issue:5 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Downes Kevin J.¹²³⁴^ORCID,Grim Austyn⁵,Shanley Laura⁶,Rubenstein Ronald C.⁷,Zuppa Athena F.²⁸⁹,Gastonguay Marc R.¹⁰

Affiliation:

1. Division of Infectious, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

2. Center for Clinical Pharmacology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

3. Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

4. Department of Pediatrics, The University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA

5. Department of Pharmacy, Texas Children’s Hospital, Houston, Texas, USA

6. Clinical Pharmacy, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

7. Division of Allergy and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA

8. Division of Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

9. Department of Anesthesiology and Critical Care, The University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA

10. Metrum Research Group, Tariffville, Connecticut, USA

Abstract

Extended interval dosing of tobramycin is recommended for treatment of pulmonary exacerbations in adults and older children with cystic fibrosis (CF), but data are limited in patients less than 5 years of age. We performed a retrospective population pharmacokinetic (PK) analysis of hospitalized children with CF <5 years of age prescribed intravenous tobramycin for a pulmonary exacerbation from March 2011 to September 2018 at our hospital.

Funder

HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02377-21

Reference23 articles.

1. Cystic Fibrosis Pulmonary Guidelines

2. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the TOPIC study: a randomised controlled trial

3. Mechanisms of Aminoglycoside Ototoxicity and Targets of Hair Cell Protection

4. Therapeutic drug monitoring of antimicrobials

5. Safety of Extended Interval Tobramycin in Cystic Fibrosis Patients Less Than 6 Years Old